This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jennifer I. Lim, MD; Richard Fiscella, RPh, MPH; Howard Tessler, MD; Donald A. Gagliano, MD; Vincent Chaques-Alepuz, MD; Margie A. Mohler, PhD

Arch Ophthalmol. 1991;109(5):714-717.

Abstract
• Fifty-eight eyes of 31 anesthetized rabbits received one drop of proparacaine hydrochloride, 0.05%, and two drops of tissue plasminogen activator (tPA) separated by 5 minutes. Four eyes of two additional rabbits had epithelial defects created before drug delivery. Tissue plasminogen activator in multiple doses was given to eight eyes of four other rabbits. We used this dosing regimen to investigate the effect of topical tPA on anterior chamber fibrin clots in three rabbits. A two-site enzyme-linked immunosorbent assay test was used to measure tPA levels in the aqueous samples, obtained by paracentesis in each eye. Of 53 eyes treated with the original dosing regimen, 21 (40%) had detectable tPA aqueous levels. Blood and aqueous from eyes of untreated control rabbits, contralateral control eyes of treated rabbits, and eyes with epithelial defects had nondetectable tPA. Multiple tPA drop dosing resulted in 75% of aqueous samples with detectable tPA and a higher average tPA concentration than the original dosing regimen. Eyes treated with tPA showed a significantly faster resolution of anterior chamber fibrin clots than did control eyes.

Author Affiliations
From the Department of Ophthalmology, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine. Dr Lim is now with the Wilmer Eye Institute, The Johns Hopkins Medical Institutions, Baltimore, Md.

Footnotes
Accepted for publication December 3, 1990.

Read in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, Fla, May 3, 1990.

Reprint requests to Illinois Eye & Ear Infirmary, 1855 W Taylor, Chicago, IL 60612 (Dr Tessler).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tissue plasminogen activator therapy for the eye
Tripathi and Tripathi
Br J Ophthalmol 2005;89:1390-1391.
FULL TEXT  

Recombinant tissue plasminogen activator following paediatric cataract surgery
Mehta and Adams
Br J Ophthalmol 2000;84:983-986.
ABSTRACT | FULL TEXT  

Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study
Heiligenhaus et al.
Br J Ophthalmol 1998;82:810-815.
ABSTRACT | FULL TEXT